Table 1.
Main characteristics of the trials included. Ipi = Ipilimumab; Nivo = Nivolumab; Sun=Sunitinib; Ave=Avelumab; Axi = Axitinib; Atez = Atezolizumab; Beva = bevacizumab; Pembro = pembrolizumab; Sun = sunitinib.
| Ref. | Arms | Number of Patients | Median PFS In Months (Range) | PFS-HR | Median OS In Months (Range) | OS-HR | OR-R% | CR-R% | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ITT | Sarc | ||
| [15,16,24] | Ipi + Nivo | 425 | 60 | 8,2; (6,9–10) | 8,4; (5,2–24) | 0,77; (0,65–0,9) | 0,38; (0,61–0,97) | 35,6 | 31,2; (23-NE) | 0,66; (0,54–0,8) | 0,55; (0,33–0,9) | 42 | 56,7 | 11 | 18,3 |
| Sun | 422 | 52 | 8,3; (7–8,8) | 4,9; (4–7) | - | - | 26,6; (22,1–33,4) | 13,6; (7,7–20,9) | - | - | 29 | 19,2 | 1 | 0 | |
| [17,22] | Ave + Axi | 442 | 47 | 13,8; (11,1-NE) | 7; (5,3–13,8) | 0,69; (0,56–0,84) | 0,57; (0,325–1,003) | - | - | 0,78; (0,554–1,084) | - | 51,4 | 46,8 | 3,4 | 4,3 |
| Sun | 444 | 61 | 8,4; (6,9–11,1) | 4; (2,7–5,7) | - | - | - | - | - | - | 25,7 | 21,3 | 1,8 | 0 | |
| [18,23] | Pembro + Axi | 432 | 51 | 15,1; (12,6–17,7) | - | 0,69; (0,57–0,84) | 0,29; (0,54–1) | - | - | 0,53; (0,38–0,74) | 0,58; (0,21–1,59) | 59,3 | 58,8 | 5,8 | 11,8 |
| Sun | 429 | 54 | 11,1; (8,7–12,5) | 8,4 | - | - | - | - | - | - | 35,7 | 31,5 | 1,9 | 0 | |
| [19,21] | Atez + Beva | 454 | 68 | 11,2; (9,6–13,3) | 8,3; (5,4–12,9) | 0,83; (0,7–0,97) | 0,34; (0,52–0,79) | 33,6; (29-NE) | 18,3 | 0,93; (0,76–1,14) | 0,56; (0,32–0,96) | 37 | 49 | 5 | 10 |
| Sun | 461 | 74 | 8,4; (7,5–9,7) | 5,3; (3,3–6,7) | - | - | 34,9; (27,8-NE) | 15; (8,7-NE) | - | - | 33 | 14 | 2 | 3 | |
| [20] | Atez + Beva | 101 | 15 | 11,7; (8,4–17,3) | - | 0,82; (0,59–1,15) | 0,26; (0,63–1,54) | - | - | - | - | - | - | - | - |
| Atezo | 103 | 16 | 6,1; (5,4–13,6) | - | 1,18; (0,86–1,63) | 0,44; (1–2,3) | - | - | - | - | - | - | - | - | |
| Sun | 101 | 14 | 8,4; (7–14) | - | - | - | - | - | - | - | - | - | - | - | |